数据挖掘和生物化学分析揭示了阿尔茨海默氏症疾病中的新生物标志物候选者
Annamaria Vernone1, Ilaria Stura1, Caterina Guiot1
1Department of Neurosciences, University of Turin, Via Cherasco 15, 10125 Torino, Italy.
International journal of molecular sciences
|August 14, 2025
概括
研究人员通过挖掘与线粒体和铁问题相关的蛋白质数据来确定潜在的阿尔茨海默病 (AD) 生物标志物. 这种新的方法可以帮助诊断AD和发现新的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 生物信息学是一种生物信息学.
背景情况:
- 阿尔茨海默病 (AD) 的诊断和预后依赖于确定可靠的生物标志物.
- 在AD中差异性蛋白质表达提供了潜在的治疗点.
研究的目的:
- 引入一种新的数据挖掘和生化分析方法,用于识别阿尔茨海默病 (AD) 生物标志物.
- 在AD中探索与线粒体和铁代谢失调相关的基因和蛋白质.
主要方法:
- 使用了三个开放的在线数据库 (UniProt,AlzGene,Allen人类大脑图谱) 来进行数据挖掘.
- 使用与蛋白质组成,功能和AD相关的特定关键词搜索数据库.
- 对已识别的蛋白质进行了氨基酸含量的生物化学分析.
主要成果:
- 通过数据匹配,确定了涉及AD的相关蛋白质列表.
- 生物化学分析表明,缺陷的蛋白质合成在缺氧的大脑组织中,表明与AD进展的相关性.
- 揭示了几种潜在的AD新生物标志物,需要进一步调查.
结论:
- 这项研究提出了一个新的数据库搜索策略的概念证明,用于在AD中发现生物标志物.
- 这种方法对识别新的AD生物标志物和治疗点具有前景.
- 该方法可适用于各种疾病中的生物标志物研究.
更多相关视频
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
978
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.9K
相关概念视频
Alzheimer's Disease: Overview
668
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
668
Alzheimer's Disease: Treatment
261
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
261
